Bayer’s non-hormonal therapy reduces hot flashes in Phase III trials
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform